NEW YORK – NeoGenomics announced on Tuesday a partnership with Lilly Oncology aimed at molecular testing for thyroid cancer patients.
Through the Thyroid Cancer Testing Program, sponsored by Lilly Oncology, NeoGenomics will offer patients in the program either the NGS Thyroid Profile test for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients.
Lilly Oncology is covering the full cost of the test, regardless of the results or treatment decision, and once NeoGenomics receives the patient sample, results are received within two weeks.
The program is available to any US-based patient 12 or older with advanced or metastatic medullary thyroid cancer who requires systemic therapy, or patients with advanced or metastatic non-medullary thyroid cancer who require systemic therapy and are radioactive iodine-refractory, if radioactive iodine is appropriate.
Fort Myers, Florida-based NeoGenomics noted that patients who haven't undergone biopsy can enroll in the program but are responsible for working with their doctor to collect a viable tumor specimen and for any costs associated with the collection.